AAAmir Reza Afshari

Amir Reza Afshari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amir Reza Afshari has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harnessing Repurposed Drugs to Enhance Temozolomide Efficacy in Glioblastoma

    by Ali Nakhaei, Atefeh Taghavi, Amir R. Afshari, Farzaneh Davoudi, Elaheh Gheybi, Mohammad Jalili‐Nik

    Background: Glioblastoma (GB) is the most aggressive primary malignant brain tumor in adults and remains associated with poor survival despite surgical resection followed by radiotherapy and temozolomide (TMZ) chemotherapy. Intrinsic and acquired resistance to TMZ, including MGMT‐dependent DNA repair and activation of pro‐survival pathways, could decrease treatment efficacy. Drug repurposing offers an attractive strategy to identify agents that may enhance TMZ activity because these drugs already have known pharmacokinetic and safety profiles. This narrative review summarizes the available evidence on repurposed drugs investigated as potential modulators of TMZ response in GB. Recent Findings: A range of repurposed agents, including chloroquine, valproic acid, levetiracetam, metformin, aspirin, amlodipine, atorvastatin, chlorpromazine, melatonin, disulfiram, bortezomib, and verteporfin, have been evaluated in GB models and selected clinical studies. Reported mechanisms include modulation of MGMT expression, autophagy, oxidative stress, apoptosis, DNA‐damage responses, cancer stem‐cell properties, and signaling pathways such as PI3K/AKT/mTOR, AMPK, EGFR, STAT3, ERK1/2, and NF‐κB. Several agents have enhanced TMZ‐associated cytotoxicity in cell culture and animal models. However, clinical evidence remains limited, and the results are inconsistent for some drugs. Blood–brain barrier penetration, achievable intratumoral drug exposure, toxicity, treatment scheduling, and molecular heterogeneity of GB remain major translational challenges. Conclusion: Repurposed drugs may provide useful candidates for improving TMZ‐based therapy in GB. However, most evidence remains preclinical, and further studies are needed to clarify blood–brain barrier penetration, optimal dosing, toxicity, predictive biomarkers, and clinical efficacy. Well‐designed prospective clinical trials are required before these combinations can be incorporated into routine GB treatment.

  • Harnessing the connection of the Wnt/beta-catenin pathway and other signaling pathways in glioblastoma multiforme

    by Ali Nakhaei, Sadaf Afshari, Elmira Mohatshami, Mohammad Jalili-Nik, Mahsa Jalali, Kasim Sakran Abass, Amir R. Afshari, Prashant Kesharwani, Amirhossein Sahebkar


  • Harnessing the role of insulin-like growth factor in glioblastoma: a comprehensive review

    by Ali Nakhaei, Sadaf Afshari, Mohammad Mohammadian, Seyed Sajad Ahmadi, Elmira Mohatshami, Mohammad Jalili-Nik, Mahsa Jalali, Sercan Karav, Amir R. Afshari, Prashant Kesharwani, et al.


  • Harnessing the role of transforming growth factor-β in glioblastoma: a focus on phytochemicals

    by Ali Nakhaei, Mehdi Abedi, Sadaf Afshari, Alireza Mohtashami, Mohammad Jalili-Nik, Mahsa Jalali, Amir R. Afshari

    Glioblastoma (GBM), the most aggressive type of primary brain tumor in adults, is characterized by a poor prognosis and considerable resistance to current therapies. Traditional treatment approaches—surgery, radiation, and chemotherapy—offer few clinical benefits and are often linked to increased recurrence rates and significant adverse effects. This underscores the urgent need for novel therapeutic strategies. Targeting the transforming growth factor-beta (TGF-β) signaling pathway is a viable strategy. TGF-β acts as a tumor suppressor during the first stages of cancer but promotes tumor progression, angiogenesis, immune evasion, and the creation of an immunosuppressive tumor microenvironment in GBM. The deregulation of TGF-β signaling has been shown to interact with essential carcinogenic pathways, including the Wnt/β-catenin, PI3K/AKT, and Notch pathways, therefore aggravating GBM pathogenesis. TGF-β plays a pivotal role in controlling glioma stem cells and influencing the permeability of the blood–brain barrier, making it an attractive target for therapeutic intervention. Novel treatment approaches, including small-molecule inhibitors and monoclonal antibodies, as well as the use of phytochemicals such as flavonoids, quercetin, and other phytochemicals targeting specific elements of the TGF-β signaling pathway, have shown encouraging results in preclinical investigations and early-stage clinical trials. These novel strategies may enhance clinical outcomes and mitigate treatment limitations in GBM therapy by leveraging this system’s combined tumor-suppressive and immune-regulatory properties.

  • Open Access

    Anti-Tumor Mechanisms of Calotropis procera in Cancer: A Comprehensive Review

    by Ali Nakhaei, Arezoo Omidkhoda, Sadaf Afshari, Alireza Mohtashami, Mohammad Jalili-Nik, Mahsa Jalali, Seyed Sajad Ahmadi, Amir R. Afshari

    Understanding processes that underlie cancer initiation, progression, and maintenance requires perceiving its distinct features. These characteristics serve as a roadmap for creating innovative treatment approaches that target the core characteristics of cancer, leading to more specialized treatments that may have longer-lasting effects but fewer side effects. Medicinal plants are becoming increasingly prevalent worldwide because of their widely acknowledged safety, affordability, and therapeutic potential. They include naturally occurring chemicals that are highly effective in herbal medicine for some cancer-related processes, such as prevention, mutagenesis suppression, antioxidant defense, and cell proliferation inhibition. The Calotropis procera is one recommended target for cancer treatment. Numerous cellular interactions in both healthy growth and illness were regulated by C. procera. In addition, recent research has elucidated the distinct anticancer activities of C. procera and their relationships with other cellular pathways. These benefits have increased expectations for the development of an effective treatment plan for all types of cancer, particularly the breast, prostate, colorectal, and glioblastoma multiforme cancers.

  • SGLT-2 inhibitors beyond diabetes: a new frontier in cancer treatment

    by Ali Nakhaei, Kiana Delavar, Azin Sadat Azim, Sadaf Afshari, Alireza Mohtashami, Mohammad Jalili-Nik, Mahsa Jalali, Seyed Sajad Ahmadi, Sercan Karav, Amir R. Afshari, et al.


  • Exploring the therapeutic role of carnosol in cancer: from molecular insights to clinical promise

    by Ali Nakhaei, Sadaf Afshari, Arezoo Omidkhoda, Elmira Mohtashami, Mohammad Mahdi Vahedi, Seyed Sajad Ahmadi, Mahsa Jalali, Amir R. Afshari

    Cancer is a leading cause of mortality worldwide, triggering healthcare system challenges and emphasizing the need for targeted treatment methods. Traditional cancer treatments can be ineffective, have long response times, and cause significant side effects that lower patients’ quality of life. Recently, attention has switched to natural compounds with anticancer properties. Carnosol, a phenolic diterpene found in rosemary and sage, is a promising alternative. Carnosol has diverse biological effects, including influencing cellular signaling pathways for proliferation, apoptosis, inflammation, and oxidative stress. Recent research has revealed its anticancer properties, preventing tumor growth and progression in breast, prostate, colorectal, and glioblastoma multiforme. Carnosol's potential as a multi-targeted therapeutic drug is supported by these findings, paving the way for its clinical usage in cancer treatment.


  • Repurposing ivermectin: a new hope for glioblastoma multiforme?

    by Elmira Mohtashami, Bahram Bibak, Mehdi Sanati, Sadaf Afshari, Kolsoum Rezaie Kahkhaie, Mohammad Mahdi Vahedi, Mohammad Jalili-Nik, Amir R. Afshari, Sercan Karav, Tannaz Jamialahmadi, et al.


  • Recent update on anti-tumor mechanisms of valproic acid in glioblastoma multiforme

    by Abulfazl Vatankhah, Sepehr Hoseinzadeh Moghaddam, Sadaf Afshari, Amir R. Afshari, Prashant Kesharwani, Amirhossein Sahebkar


  • Impact of Rapamycin on Longevity: Updated Insights

    by Mehdi Sanati, Amir R. Afshari, Samaneh Aminyavari, Maciej Banach, Amirhossein Sahebkar

    The gradual accumulation of varying detrimental alterations during the aging process within cells and tissues contributes to a progressive decline in their functionality, which may ultimately result in death. The licensed mTOR inhibitor, rapamycin, also known as sirolimus, has recently become a promising option for anti-aging applications. Through in vitro and in vivo assessments, numerous scientific reports have illustrated diverse biochemical and clinical aspects of rapamycin's pharmacological effects in ameliorating aging-related changes and expanding longevity. Nevertheless, its clinical application has been impeded by severe adverse effects, which might be addressed by implementing an appropriate therapeutic regimen. In this regard, integrating updated insights and uncovering essential benefits and drawbacks of rapamycin as a geroprotective drug is critical for conducting further preclinical research and well-organized clinical trials and moving toward the clinic. This review highlighted recent findings on the role of rapamycin in improving organ health and postponing aging-related processes.